Shridar Ganesan MD PhD
Professor of Medicine Director, Center for Molecular Oncology, NYU Perlmutter Cancer Center
Join to view full profile
195 Little Albany StNew Brunswick, NJ 08901
Phone+1 732-235-6777
Fax+1 732-235-7355
Dr. Ganesan is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1996 - 1999- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1993 - 1996
Yale School of MedicineClass of 1993
Certifications & Licensure
NJ State Medical License 2005 - 2027
NY State Medical License 2025 - 2026
MA State Medical License 1996 - 2005
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Patient Engagement Portal, Navigating Cancer, Inc., 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2013-2014, 2016-2017
Clinical Trials
- Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer Start of enrollment: 2024 Nov 15
Roles: Contact
Publications & Presentations
PubMed
- Recurrence-Free Survival Dynamics Following Adjuvant Chemotherapy for Resected Cancers of the Gastrointestinal Tract: A Systematic Review of Randomized Controlled Trials.Jennie K Choe, Sreya Sanyal, Yingting Zhang, Patrick M Boland, Matthew P Deek
The Journal of Surgical Research. 2026-10-01 - 1 citationsPremature termination of early-phase cancer clinical trials: "It's the economy, stupid!"Wadih Arap, Shridar Ganesan, Renata Pasqualini
Journal of the National Cancer Institute. 2026-08-01 - 2 citationsEvolution of clonal hematopoiesis during cancer treatment and its impact on outcomes.Mona Arabzadeh, Yi-Han Tang, Christelle Colin-Leitzinger, Sadegh Marzban, Daniel Walgenbach
The Journal of Clinical Investigation. 2026-07-15
Journal Articles
- RET Rearrangements Are Actionable Alterations in Breast CancerShridar Ganesan, Siraj M Ali, Kim M Hirshfield, Nature
- PALB2 Connects BRCA1 and BRCA2 in the G2/M Checkpoint ResponseShridar Ganesan, MD, Nature
- Endogenous Retrovirus Expression Is Associated with Response to Immune Checkpoint Blockade in Clear Cell Renal Cell CarcinomaBenjamin G. Vincent, Jonathan S. Serody, Gregory Riedlinger, Shridar Ganesan, The Journal of Clinical Investigation
Press Mentions
He Had 2 Months to Live. Cancer Research "That Seemed Like Science Fiction" Saved His LifeApril 26th, 2025- Why NYU Langone Is Betting on Molecular OncologyJanuary 15th, 2025
- NYU Langone Launches Molecular Oncology Program, Names LeaderOctober 11th, 2024
Grant Support
- Evolution and clinical impact of clonal hematopoiesis of indeterminate potential in breast tumor microenvironmentRUTGERS BIOMEDICAL AND HEALTH SCIENCES2019–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
